Meet With Us 
Building a Biotech Pipeline: Strategic Clinical Asset Development
Challenge:
A biotech company transitioning from the wellness industry faced a critical challenge: they needed to identify and acquire pre-clinical assets to establish a robust product pipeline. However, lacking in-house scientific expertise, the company required specialized support to conduct comprehensive assessments and navigate acquisition negotiations effectively.
Solution:
We provided end-to-end scientific and clinical consulting to guide the company through this pivotal transition. Our team assessed potential acquisition targets across multiple disease areas, leveraging deep expertise in scientific evaluation and commercialization strategies. Acting as the interim Chief Medical Officer, we represented the company in acquisition negotiations and licensing discussions. Additionally, we conducted an in-depth review of scientific literature to evaluate unmet medical needs and outline potential commercialization pathways for various assets, with a particular focus on rare and chronic diseases.
Outcomes
-
Comprehensive Analysis: Delivered a detailed literature review and gap analysis to support asset identification and strategic decision-making.
-
Targeted Recommendations: Helped identify a shortlist of five high-potential assets for consideration based on the literature review and gap analysis.
-
Negotiation Support: Provided critical guidance and representation during negotiations with relevant stakeholders.
-
Successful Acquisition: Facilitated the acquisition of the company’s first pre-clinical asset, laying the foundation for its new biotech product pipeline.
Key Takeaway
Through scientific fractional resourcing, this biotech company successfully pivoted to its new focus, acquiring its first pre-clinical asset and establishing a strong foundation for its product pipeline in a competitive market.